Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12

Aydin S. Z., Direskeneli H., Sreih A., Alibaz-Oner F., Gul A., Kamali S., ...Daha Fazla

JOURNAL OF RHEUMATOLOGY, cilt.42, sa.12, ss.2465-2469, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 42 Sayı: 12
  • Basım Tarihi: 2015
  • Doi Numarası: 10.3899/jrheum.141144
  • Dergi Adı: JOURNAL OF RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2465-2469
  • Anahtar Kelimeler: VASCULITIS, TAKAYASU ARTERITIS, GIANT CELL ARTERITIS, LARGE VESSEL, OUTCOMES, QUALITY-OF-LIFE, GIANT-CELL ARTERITIS, TAKAYASUS-ARTERITIS, DISEASE, HEALTH, PERSPECTIVE, FILTER
  • Marmara Üniversitesi Adresli: Evet

Özet

Objective. The rarity of large vessel vasculitis (LVV) is a major factor limiting randomized controlled trials in LVV, resulting in treatment choices in these diseases that are guided mainly by observational studies and expert opinion. Further complicating trials in LVV is the absence of validated and meaningful outcome measures. The Outcome Measures in Rheumatology (OMERACT) vasculitis working group initiated the Large Vessel Vasculitis task force in 2009 to develop data-driven, validated outcome tools for clinical investigation in LVV. This report summarizes the progress that has been made on a disease activity assessment tool and patient-reported outcomes in LVV as well as the group's research agenda.